GlassScriptPhysician profile
Misty Munger
NPI 1104356393
$5,866.15
in general payments reported to CMS, 2019-2025
27 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $449 · 2023: $1,192 · 2024: $2,726 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Travel and Lodging: $255 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.29 |
| Travel and Lodging | $255.13 |
| Education | $251.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,511.00 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,432.21 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $526.65 | 2024-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $384.84 | 2023-2024 | Inspire |
| United Therapeutics Corporation | $322.83 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.97 | 2021-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $231.50 | 2024-2025 | Dupixent |
| Baxter Healthcare | $222.46 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $127.47 | 2023-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $78.49 | 2023-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $78.23 | 2023 | |
| Amgen INC. | $69.89 | 2025 | Tezspire |
| Harmony Biosciences LLC | $64.91 | 2024 | |
| Merck Sharp & Dohme LLC | $64.73 | 2025 | Winrevair |
| Mylan Specialty L.P. | $61.02 | 2023-2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $59.86 | 2024-2025 | Arikayce |
| Viatris Specialty LLC | $50.74 | 2025 | Yupelri |
| Electromed, INC. | $47.26 | 2024-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $44.59 | 2024 | |
| Genzyme Corporation | $31.80 | 2023 | |
| Jazz Pharmaceuticals INC. | $27.61 | 2025 | |
| Axsome Therapeutics, INC. | $27.41 | 2025 | Sunosi |
| Advanced Respiratory, INC | $25.00 | 2021 | |
| Verona Pharma, INC. | $23.61 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $22.22 | 2025 | Acthar |
| Inogen, INC. | $22.12 | 2022 | |
| Lilly USA, LLC | $16.73 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Munger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.